For patients with symptoms of a sexually transmitted infection, the standard diagnostic path is a trade-off. They can wait days for a lab to process a sample, or they can receive a presumptive diagnosis based on a less sensitive rapid test. A Santa Clara startup called Scout Health is betting that a third option, a molecular test that delivers results in under 30 minutes at a clinic or pharmacy, can become the new standard. The company’s progress is now backed by a significant, non-dilutive vote of confidence from a global health nonprofit.
Scout Health, which began as Uh-Oh Labs in 2017, has secured up to $7 million in total funding from CARB-X to develop its STI Scout test. The latest tranche, a $6 million award announced in December 2025, is earmarked for final verification and validation work on the rapid molecular test for Neisseria gonorrhoeae and Chlamydia trachomatis [Scout Health, December 2025]. For a company that has also reported $16 million in non-dilutive funding from the National Institutes of Health, the CARB-X awards signal a focused push toward a specific, high-need clinical application [Y Combinator, January 2022].
The Platform Wedge: Reusable Hardware, Disposable Tests
Scout’s approach rests on a hardware-plus-software system designed to move molecular testing out of centralized laboratories. The core architecture includes a reusable desktop device called the Scout Hub, single-use Scout Test Kits containing assay reagents, and a companion Scout Connect mobile app [Scout Health]. The company’s only FDA-authorized product to date is a COVID-19 test, but its pipeline aims at a broader menu including respiratory, sexual, and women’s health conditions.
The STI Scout test represents the most advanced application of this platform. The goal is to enable healthcare providers in clinics or urgent care centers to run a molecular diagnostic in under 30 minutes, allowing for same-visit treatment guidance [LabMedica, December 2025]. This targets a critical gap in STI management, where delayed results contribute to ongoing transmission and complications.
A Team Built for Bioengineering and Scale
The founders bring complementary backgrounds in bioengineering and hardware development. CEO Alex Jiao holds a PhD in bioengineering and previously founded Silene Biotech, a stem-cell banking company acquired by Curi Bio in 2019 [LinkedIn]. CTO Cameron Ball, also a PhD, is a biomedical engineer with prior experience at Sandia National Laboratories and was the original founder of Uh-Oh Labs [Y Combinator].
The company has also assembled a clinical advisory board that lends credibility to its regulatory and commercial strategy. Advisors include Michael Mina, the former Harvard epidemiologist and chief science officer at eMed, and Sharon Moise, chief medical officer at Medcor [Scout Health].
| Role | Name | Key Background |
|---|---|---|
| CEO & Co-Founder | Alex Jiao, PhD | Founded Silene Biotech (acquired by Curi Bio); PhD in bioengineering. |
| CTO & Co-Founder | Cameron Ball, PhD | Biomedical engineer; founded Uh-Oh Labs (Scout's predecessor); Sandia National Labs alum. |
| VP of Operations | Shawn Gorham | Listed on company leadership page. |
| Director of Software | Cameron McCleary | Listed on company leadership page. |
The Funding Path: Grants Before Venture
Scout’s capitalization table is unusual for a venture-scale startup, heavily weighted toward non-dilutive grants. This strategy has provided runway without significant equity dilution in the early, high-risk R&D phase. The company participated in Y Combinator’s Winter 2022 batch and has attracted seed investors including Soma Capital and Gaingels [Y Combinator]. However, the largest publicly disclosed infusions are from government and nonprofit entities.
NIH Non-Dilutive Funding (Reported) | 16 | M USD
CARB-X Award (April 2024) | 1 | M USD
CARB-X Award (December 2025) | 6 | M USD
This funding profile underscores the project-based, milestone-driven nature of its current development work, particularly for the CARB-X-backed STI test. The next financial step will likely involve a larger equity round to fund commercial manufacturing, sales, and the pursuit of over-the-counter regulatory clearance for an at-home version of the STI test.
The Regulatory Hurdle Ahead
The primary risk for Scout is not scientific feasibility but regulatory execution and commercial adoption. The company has cleared one FDA hurdle with its COVID-19 test, but securing 510(k) clearance or De Novo authorization for a novel rapid molecular STI test is a more complex and lengthy process. Furthermore, the point-of-care diagnostic market is crowded with established players like Cepheid (now part of Danaher) and Abbott, which have deep commercial relationships with health systems.
Scout’s answer to this competition rests on three points.
- Platform economics. A reusable hub with disposable test kits could offer a lower total cost of ownership for high-volume settings compared to some proprietary systems.
- Speed to result. A 30-minute turnaround for a molecular test is a meaningful clinical improvement over current lab-based PCR, which can take days.
- Future optionality. The same hardware platform is designed to run multiple tests, creating a potential menu effect for clinics that start with STI testing [Med-Tech Innovation].
The commercial bet is that these advantages will allow Scout to first win in decentralized settings like STI clinics and urgent care centers before attempting to displace incumbents in large hospital networks.
The Patient Population and Standard of Care
The target for Scout’s STI test is patients presenting with symptoms or seeking screening for gonorrhea and chlamydia, two of the most common bacterial sexually transmitted infections. In the United States, the CDC recommends annual screening for sexually active women under 25 and for older women with risk factors, representing millions of tests each year.
Today, the standard of care is fragmented. The most sensitive option is a nucleic acid amplification test (NAAT) performed in a centralized or regional laboratory, which can take 24 to 72 hours to return a result. Rapid point-of-care tests exist, but they are typically antigen-based and have lower sensitivity, leading to missed infections. This delay or uncertainty can mean a patient leaves a clinic without treatment, potentially spreading the infection or developing complications like pelvic inflammatory disease. Scout’s proposed test aims to collapse that timeline, offering lab-grade accuracy during the clinical visit itself.
For Scout Health, the next twelve months will be defined by clinical validation work funded by the CARB-X award. Success will be measured by the performance data it generates and its subsequent submission to the FDA. If the data holds up, the company will have a compelling case for a significant venture round to build the commercial engine for a test that could change the front lines of sexual health care.
Sources
- [Scout Health, December 2025] Scout Health Accelerates Point-of-Care STI Test Development With $6M CARB-X Award | https://www.scouthealth.com/press/carb-x-funding
- [Y Combinator, January 2022] Scout Health | https://www.ycombinator.com/companies/scout-2
- [Scout Health] Company Website - Product and Team Pages
- [LabMedica, December 2025] STI molecular test delivers rapid POC results for treatment guidance | https://www.labmedica.com/molecular-diagnostics/articles/294807621/sti-molecular-test-delivers-rapid-poc-results-for-treatment-guidance.html
- [LinkedIn] Alex Jiao Profile
- [Med-Tech Innovation] CARB-X funds Scout to develop a low-cost point-of-care and home diagnostic for gonorrhea and chlamydia | https://carb-x.org/carb-x-news/carb-x-funds-scout/
- [CARB-X, April 2024] CARB-X funds Scout to develop a low-cost point-of-care and home diagnostic for gonorrhea and chlamydia | https://carb-x.org/carb-x-news/carb-x-funds-scout/